Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JMT 108

Next Previous
Drug Profile

JMT 108

Alternative Names: JMT-108; SYS-6090

Latest Information Update: 30 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai JMT-BIO Technology
  • Developer Conjupro Biotherapeutics; Shanghai JMT-BIO Technology
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 15 modulators; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Cancer; Solid tumours

Most Recent Events

  • 16 Mar 2026 Shanghai JMT-Bio plans a phase Ib/II trial for Non-small cell lung cancer and Small cell lung cancer (Combination therapy, Inoperable/unresectable, Late-stage disease, Metastatic disease) (Parenteral, Injection) (NCT07472647)
  • 17 Dec 2025 Phase-I/II clinical trials in Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (IV) (NCT07280832)
  • 12 Dec 2025 Shanghai JMT-Bio plans phase I/II in Malignant melanoma (Second-line therapy and greater, Unresectable, Late-stage disease, Metastatic disease) in December 2025 (IV) (NCT07280832)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top